MedTrace Logo

Efficacy of YKP3089 in Patients With Photosensitive Epilepsy

NCT00616148 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2014-01-31

No results posted yet for this study

Summary

The aim of this study is to evaluate the ability of a single oral dose of YKP3089 to abolish or clearly reduce the IPS-induced photo-paroxysmal EEG response in photosensitive epilepsy patients, and to measure the onset and duration of the effect. Several cohorts will be used, to sequentially investigate different doses.

Conditions

Interventions

DRUG

YKP3089

Oral dosage form

DRUG

Placebo

Sponsors & Collaborators

  • The Epilepsy Study Consortium

    collaborator OTHER

  • SK Life Science, Inc.

    lead INDUSTRY

Principal Investigators

  • Jacqueline French, M.D. · NYU MEDICAL CENTER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2009-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00616148 on ClinicalTrials.gov